Trial Profile
Randomized Phase II Trial of Three-weekly Cisplatinum and Pemetrexed versus Split-dose d1 and d8 Cisplatinum and Pemetrexed In Advanced and Inoperable Non-squamous Non-small-cell lung cancer (NSCLC)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Cisplatin (Primary) ; Pemetrexed (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms PemSplitCisp
- 05 Aug 2017 Status changed from recruiting to completed.
- 04 Dec 2012 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health, NCT01742767)
- 07 Sep 2012 New trial record